Cascadian Therapeutics (ONTY) Inactive 10-Q2010 Q1 Quarterly report

Filed: 10 May 10, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Good

New words: arrangement, ASU, clarified, collect, collectibility, culmination, defense, deficiency, deliverable, Department, deposit, distraction, expertise, exploratory, fashion, figure, Gamehost, half, high, impede, indirectly, investor, joint, knowledge, lab, monetization, monthly, myeloma, numerator, occupancy, overhead, oversight, Pfizer, precautionary, prolonged, ranging, ratably, reaction, recodified, removed, requested, resale, respond, rest, resume, resumed, resumption, staffing, substance, suitable, Supplementary, suspected, territory, ULC, unexpected

Removed: affiliate, Alberta, amendment, amortization, amortized, ancillary, assessing, asset, assume, assumption, cessation, chartered, closed, consecutive, consolidate, country, defer, demonstrated, depositary, diminished, earliest, Edmonton, EITF, eliminated, Emerging, entry, exceptionally, exclusively, expending, flexibility, flow, Force, forming, framework, FSP, Glaxo, handled, headcount, HIF, IDM, improving, inclusion, innovative, inoperable, inventory, July, Kline, long, methodology, milestone, North, notified, notifying, November, objective, pancreatic, Panel, paper, Pharma, placebo, preceding, predecessor, priority, pro, prospective, provincial, publication, rata, raw, recently, remained, remaining, responsibility, restated, restructured, retained, revised, Roche, shared, shelf, Smith, subscription, subtracted, Task, Toronto, transferred, transitioned, Treasury, trust, upfront

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

ONTY similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32.1

CERTIFICATION PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
(18 U.S.C. SECTION 1350)

I, Robert L. Kirkman, M.D., certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report of Oncothyreon Inc. on Form 10-Q for the quarterly period ended March 31, 2010, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Quarterly Report on Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of Oncothyreon Inc.



May 10, 2010		/s/ Robert L. Kirkman, M.D.
		Robert L. Kirkman, M.D.,
		President and Chief Executive Officer (Principal Executive Officer)

A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 has been provided to Oncothyreon Inc. and will be retained by Oncothyreon Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

This certification accompanies this Report on Form 10-Q pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by Oncothyreon Inc. for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that Oncothyreon Inc. specifically incorporates it by reference.